1. Home
  2. LITS vs ADAG Comparison

LITS vs ADAG Comparison

Compare LITS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LITS
  • ADAG
  • Stock Information
  • Founded
  • LITS 2000
  • ADAG 2011
  • Country
  • LITS United States
  • ADAG China
  • Employees
  • LITS N/A
  • ADAG N/A
  • Industry
  • LITS Biotechnology: Pharmaceutical Preparations
  • ADAG Biotechnology: Pharmaceutical Preparations
  • Sector
  • LITS Health Care
  • ADAG Health Care
  • Exchange
  • LITS Nasdaq
  • ADAG Nasdaq
  • Market Cap
  • LITS 96.2M
  • ADAG 84.8M
  • IPO Year
  • LITS N/A
  • ADAG 2021
  • Fundamental
  • Price
  • LITS $1.85
  • ADAG $2.10
  • Analyst Decision
  • LITS
  • ADAG Strong Buy
  • Analyst Count
  • LITS 0
  • ADAG 4
  • Target Price
  • LITS N/A
  • ADAG $8.00
  • AVG Volume (30 Days)
  • LITS 539.5K
  • ADAG 103.4K
  • Earning Date
  • LITS 11-17-2025
  • ADAG 08-12-2025
  • Dividend Yield
  • LITS N/A
  • ADAG N/A
  • EPS Growth
  • LITS N/A
  • ADAG N/A
  • EPS
  • LITS N/A
  • ADAG N/A
  • Revenue
  • LITS N/A
  • ADAG $103,204.00
  • Revenue This Year
  • LITS N/A
  • ADAG $7,411.34
  • Revenue Next Year
  • LITS N/A
  • ADAG $28.29
  • P/E Ratio
  • LITS N/A
  • ADAG N/A
  • Revenue Growth
  • LITS N/A
  • ADAG N/A
  • 52 Week Low
  • LITS $1.46
  • ADAG $1.30
  • 52 Week High
  • LITS $9.00
  • ADAG $3.16
  • Technical
  • Relative Strength Index (RSI)
  • LITS N/A
  • ADAG 56.75
  • Support Level
  • LITS N/A
  • ADAG $1.78
  • Resistance Level
  • LITS N/A
  • ADAG $1.99
  • Average True Range (ATR)
  • LITS 0.00
  • ADAG 0.21
  • MACD
  • LITS 0.00
  • ADAG 0.04
  • Stochastic Oscillator
  • LITS 0.00
  • ADAG 80.00

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: